Endogenous angiogenesis inhibitors
- PMID: 15563312
- DOI: 10.1111/j.1600-0463.2004.apm11207-0809.x
Endogenous angiogenesis inhibitors
Abstract
When the FDA commissioner announced in February 2004 the approval of Avastin for the treatment of patients with colon cancer, he called angiogenesis inhibitors a fourth modality of anti-cancer therapy. Because angiogenesis inhibitors are relatively less toxic than conventional chemotherapy and have a lower risk of drug resistance, they may also represent a new class of anti-cancer agents, some of which have sufficiently reduced toxicity that they may be safely used long term. These include immunotherapy, vaccines, telomerase inhibitors, apoptosis inducers, low dose metronomic chemotherapy, novel hormonal therapies, gene therapy and others. However, at least 16 endogenous angiogenesis inhibitors have been discovered in the circulation, and/or in the extracellular matrix. These may become the safest and least toxic of anti-cancer therapies. Four are already being administered by injection in clinical trials for cancer. Recently, it has been reported that at least two endogenous angiogenesis inhibitors can be significantly increased in humans (endostatin), and in mice (thrombospondin), by oral administration of small molecules which themselves are already FDA approved for other uses. This finding suggests several new clinical applications for the future, including the possibility of guiding the use of angiogenesis inhibitors by blood or urinary biomarkers, currently being developed, that may detect the presence of cancer before it is symptomatic, or before it can be located by conventional methods.
Similar articles
-
Molecular mechanisms and therapeutic development of angiogenesis inhibitors.Adv Cancer Res. 2008;100:113-31. doi: 10.1016/S0065-230X(08)00004-3. Adv Cancer Res. 2008. PMID: 18620094 Review.
-
Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.Clin Cancer Res. 2008 Mar 1;14(5):1529-39. doi: 10.1158/1078-0432.CCR-07-4126. Clin Cancer Res. 2008. PMID: 18316578
-
Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.Exp Cell Res. 2006 Mar 10;312(5):594-607. doi: 10.1016/j.yexcr.2005.11.015. Epub 2005 Dec 22. Exp Cell Res. 2006. PMID: 16376330 Review.
-
Endostatin: the logic of antiangiogenic therapy.Drug Resist Updat. 2005 Feb-Apr;8(1-2):59-74. doi: 10.1016/j.drup.2005.03.001. Epub 2005 Apr 7. Drug Resist Updat. 2005. PMID: 15939343 Review.
-
Angiogenesis research: from laboratory to clinic.Forum (Genova). 1999 Jul-Dec;9(3 Suppl 3):59-62. Forum (Genova). 1999. PMID: 10607848
Cited by
-
Antibody-Loaded Nanoplatforms for Colorectal Cancer Diagnosis and Treatment: An Update.Pharmaceutics. 2023 May 17;15(5):1514. doi: 10.3390/pharmaceutics15051514. Pharmaceutics. 2023. PMID: 37242756 Free PMC article. Review.
-
Regenerative Medicine and Angiogenesis; Focused on Cardiovascular Disease.Adv Pharm Bull. 2022 Aug;12(4):686-699. doi: 10.34172/apb.2022.072. Epub 2021 Oct 3. Adv Pharm Bull. 2022. PMID: 36415645 Free PMC article. Review.
-
VEGF-A controls the expression of its regulator of angiogenic functions, dopamine D2 receptor, on endothelial cells.J Cell Sci. 2022 Jun 1;135(11):jcs259617. doi: 10.1242/jcs.259617. Epub 2022 May 31. J Cell Sci. 2022. PMID: 35593650 Free PMC article.
-
Cell surface nucleolin is a novel ADAMTS5 receptor mediating endothelial cell apoptosis.Cell Death Dis. 2022 Feb 23;13(2):172. doi: 10.1038/s41419-022-04618-x. Cell Death Dis. 2022. PMID: 35197459 Free PMC article.
-
Discovery of new vascular disrupting agents based on evolutionarily conserved drug action, pesticide resistance mutations, and humanized yeast.Genetics. 2021 Aug 26;219(1):iyab101. doi: 10.1093/genetics/iyab101. Genetics. 2021. PMID: 34849907 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
